DL CO was not affected by treatment, but 6‐min walking distance and FVC showed a trend toward an increase. 118 In a second randomized, double‐blind placebo‐controlled phase 2 study (PRM‐151‐202) conducted at 18 sites in 7 countries, 117 patients with IPF between the ages of 40 and 80 years received placebo or 10 mg/kg PRM‐151 every 4 weeks for 24 weeks after a three‐dose loading regimen, along with usual IPF treatment in 78%.
1
—
—